Literature DB >> 21761941

Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome.

Gwénaëlle Le Gall1, Samah O Noor, Karyn Ridgway, Louise Scovell, Crawford Jamieson, Ian T Johnson, Ian J Colquhoun, E Kate Kemsley, Arjan Narbad.   

Abstract

(1)H NMR spectroscopy of aqueous fecal extracts has been used to investigate differences in metabolic activity of gut microbiota in patients with ulcerative colitis (UC) (n = 13), irritable bowel syndrome (IBS) (n = 10), and healthy controls (C) (n = 22). Up to four samples per individual were collected over 2 years giving a total of 124 samples. Multivariate discriminant analysis, based on NMR data from all three groups, was able to predict UC and C group membership with good sensitivity and specificity; classification of IBS samples was less successful and could not be used for diagnosis. Trends were detected toward increased taurine and cadaverine levels in UC with increased bile acid and decreased branched chain fatty acids in IBS relative to controls; changes in short chain fatty acids and amino acids were not significant. Previous PCR-denaturing gradient gel electrophoresis (PCR-DGGE) analysis of the same fecal material had shown alterations of the gut microbiota when comparing UC and IBS groups with controls. Hierarchical cluster analysis showed that DGGE profiles from the same individual were stable over time, but NMR spectra were more variable; canonical correlation analysis of NMR and DGGE data partly separated the three groups and revealed a correlation between the gut microbiota profile and metabolite composition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21761941     DOI: 10.1021/pr2003598

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  106 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.

Authors:  Michael Camilleri; David A Katzka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

Review 2.  Clinical metabolomics paves the way towards future healthcare strategies.

Authors:  Sebastiano Collino; François-Pierre J Martin; Serge Rezzi
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

Review 3.  Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.

Authors:  Anet A Soubières; Andrew Poullis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 4.  Gut microbiota-derived metabolites as key actors in inflammatory bowel disease.

Authors:  Aonghus Lavelle; Harry Sokol
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-19       Impact factor: 46.802

Review 5.  Hypothesis: bacteria control host appetites.

Authors:  Vic Norris; Franck Molina; Andrew T Gewirtz
Journal:  J Bacteriol       Date:  2012-11-09       Impact factor: 3.490

Review 6.  Brain-gut microbiome interactions and functional bowel disorders.

Authors:  Emeran A Mayer; Tor Savidge; Robert J Shulman
Journal:  Gastroenterology       Date:  2014-02-28       Impact factor: 22.682

Review 7.  Monitoring host responses to the gut microbiota.

Authors:  Joshua S Lichtman; Justin L Sonnenburg; Joshua E Elias
Journal:  ISME J       Date:  2015-06-09       Impact factor: 10.302

8.  Clostridium difficile heterogeneously impacts intestinal community architecture but drives stable metabolome responses.

Authors:  David Rojo; María J Gosalbes; Rafaela Ferrari; Ana E Pérez-Cobas; Ester Hernández; Rosa Oltra; Javier Buesa; Amparo Latorre; Coral Barbas; Manuel Ferrer; Andrés Moya
Journal:  ISME J       Date:  2015-03-10       Impact factor: 10.302

Review 9.  Application of metagenomics in the human gut microbiome.

Authors:  Wei-Lin Wang; Shao-Yan Xu; Zhi-Gang Ren; Liang Tao; Jian-Wen Jiang; Shu-Sen Zheng
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 10.  Metabolomics as a diagnostic tool in gastroenterology.

Authors:  Vicky De Preter; Kristin Verbeke
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.